Senior Director, Global Product Strategy

About the role

Built on a strong scientific, technological, and clinical foundation, we are building a commercial organization to launch and drive revenue for our oncology portfolio. As Senior Director, you will lead strategy for our early-stage pipeline, spanning all assets from preclinical candidates through early Phase 2, so that the most promising science becomes differentiated medicines for patients.

You will bring a patient-centered, externally focused approach, partnering with oncology clinicians to understand their needs and those of their patients. You will work closely with Research and Development to shape early clinical programs that are designed for later regulatory and commercial success, and you will help the organization decide where to invest. As a senior leader within Global Product Strategy, you will have visibility at all levels of the organization.

Your contribution

• Set the global product strategy for the early portfolio, covering all assets from preclinical candidates through early Phase 2, across multiple modalities and tumor types.
• Define target product profiles, indication prioritization, and differentiation strategy for each asset, grounded in unmet patient need and the evolving competitive and treatment landscape.
• Partner with Research, Translational, and Clinical Development to design early clinical plans, including biomarker and patient-selection strategies, that create a clear path to proof of concept and to later-stage regulatory and commercial success.
• Build and maintain go/no-go criteria, early commercial assessments, and market and forecast models to inform portfolio prioritization and investment decisions.
• Gather insights from oncology clinicians, KOLs, patients, and payers early in development to test assumptions and shape clinical programs.
• Monitor scientific, clinical, and competitor trends, and translate them into actionable implications for asset strategy and portfolio planning.
• Support business development and partnering efforts by providing strategic and commercial assessments of internal and external opportunities.
• Where BioNTech has co-development or co-commercialization rights, ensure alignment with partners on asset strategy and resources.
• Prepare assets for a smooth transition into late-stage development by working with late-stage Global Product Strategy teams, Regulatory Affairs, Medical Affairs, and Market Access.
• Lead, coach, and mentor team members, and build a high-performing, collaborative early-asset strategy function.
• Own budget planning and tracking for the function, and manage vendor partnerships so work is delivered on plan, cost-effectively, and within budget.

A good match

• BS/BA with 10+ years in pharma or biotech and increasing levels of responsibility. Advanced degree a plus.
• Oncology experience, including immunotherapy; knowledge of novel modalities such as mRNA, antibody-drug conjugates, or cell therapy is a strong plus.
• Experience in early-stage asset strategy, early development, or translational strategy, with a record of helping advance assets from preclinical stage to clinical proof of concept.
• Working knowledge of drug development, regulatory pathways, and the reimbursement and healthcare environment, and how they shape early program design.
• Experience at both country/affiliate level and regional or global level, or equivalent breadth, preferred.
• Prior product launch experience is valued, as it informs how early programs are designed.
• Proven ability to influence and build alignment across R&D, commercial, and business development teams.
• Strong analytical, strategic, organizational, and collaboration skills.